Loading organizations...
§ Venture Capital · San Diego, CA, USA
Life sciences advisory and investment firm providing strategic advisory and investments for biopharmaceutical companies, focused on novel medicines.
Key people at BioBrit.
BioBrit is a life sciences consulting and investment firm based in La Jolla, California, that provides strategic advisory services and allocates capital to early-stage and established biopharmaceutical companies. The firm leverages deep industry expertise to support its portfolio companies in developing and commercializing novel medicines, with a particular emphasis on therapies for autoimmune disorders and inflammatory conditions. Operating on a boutique scale with fewer than 25 employees, the organization generates under $5 million in annual revenue through its dual business model of consulting fees and investment returns. BioBrit maintains a diverse portfolio of public and private equity investments, holding financial interests and board positions in recognizable life sciences companies such as Equillium, Castle Biosciences, and Vivani Medical. The investment and advisory organization was officially founded in 2012 by life sciences executives Daniel M. Bradbury and Bethany Heintz.
Key people at BioBrit.
BioBrit has 7 tracked investments across 5 companies. The latest tracked deal is $40.0M Seed in Creyon Bio in March 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 8, 2022 | Creyon Bio | $40.0M Seed | Kiersten Stead, Zavain DAR | Alexandria Venture Investments, Casdin Capital |
| Mar 1, 2022 | Creyon Bio | $40.0M Series A | DCVC BIO, LUX Capital | Dcvc (data Collective), Deerfield Management, Dimension Capital, Menlo Ventures, Andrew Schoen, Union Square Ventures, JAN Erik Solem, Alexandria Venture Investments, Casdin Capital |
| Sep 1, 2021 | Amplo Biotechnology | $2.0M Seed | — | — |
| Mar 23, 2021 | Stuart Therapeutics | $11.0M Series A | Infocus Capital Partners | Mimo Capital, Warf Ventures |
| Oct 1, 2020 | Primmune Therapeutics | $27.0M Series A | CAM Capital, Amir Nashat | Domain Associates, Polaris Partners, Biorock Ventures, Mcdermott, Andrew Rubinstein, Samsara BioCapital |
| Apr 1, 2020 | Alume Biosciences | $6.0M Series A | — | Chrysa Mineo, Daniel M. Bradbury |
| Mar 2, 2020 | Primmune Therapeutics | $7.0M Seed | — | Charlie Mcdermott, Biorock Ventures, Scott Morenstein |
BioBrit is a life sciences consulting and investment firm based in La Jolla, California, founded in 2012. It specializes in providing strategic advisory services and venture capital investments focused on the biotechnology and life sciences sectors. BioBrit supports companies within this industry by leveraging deep expertise and resources to help them grow and succeed. Its client base primarily includes biotech startups and established life sciences companies seeking transformative strategies and capital to advance their innovations[1][3][4][5].
BioBrit was founded in 2012 in La Jolla, California. The firm is led by Dan Bradbury, a seasoned life sciences executive with over 40 years of experience in biotech and pharmaceutical industries, including leadership roles at Amylin Pharmaceuticals and Equillium, Inc. Bradbury’s extensive background in launching novel medicines and managing biotech companies shapes BioBrit’s strategic focus. Bethany Heintz, with 30 years of experience supporting senior executives in life sciences, serves as Chief Administrative Officer, managing operations and portfolio support. The firm’s founding reflects a commitment to combining investment with hands-on consulting to accelerate life sciences innovation[1][4][6].
BioBrit operates at the intersection of biotech innovation and capital markets, riding the ongoing trend of increased investment in life sciences driven by advances in genomics, personalized medicine, and biologics. The timing is favorable due to growing demand for novel therapies addressing unmet medical needs and the expanding biotech ecosystem in Southern California. BioBrit’s dual role as investor and consultant allows it to influence the startup ecosystem by accelerating the development and commercialization of cutting-edge biotech products, thus contributing to the broader healthcare innovation landscape[1][3][5].
Looking ahead, BioBrit is well-positioned to capitalize on emerging biotech trends such as immunotherapies, gene editing, and digital health integration. Its leadership’s experience and strategic approach suggest continued growth in both portfolio value and influence. As the life sciences sector evolves with new technologies and regulatory pathways, BioBrit’s model of combining investment with operational expertise will likely enhance its role as a key enabler of biotech innovation. This positions the firm to remain a significant player in shaping the future of healthcare solutions[6].
